• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MYCN Gene Record

  • Summary
  • Interactions
  • Claims
  • MYCN 4613 Clinically ActionableDrug Resistance

    Alternate Names:

    4613
    MYCN PROTO-ONCOGENE, BHLH TRANSCRIPTION FACTOR
    MYCN
    MODED
    N-myc
    NMYC
    ODED
    bHLHe37
    164840
    7559
    ENSG00000134323
    OTTHUMG00000039579
    3741
    PA31359

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (6 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    CLINICALLY ACTIONABLE

    Publications:

    Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
    Reynolds et al., 2000, Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide., Med. Pediatr. Oncol.
    Kool et al., 2014, Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition., Cancer Cell
    Henssen A et al., 2016, Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition., Clin Cancer Res
    Shahbazi J et al., 2016, The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects., Clin Cancer Res
  • DINUTUXIMAB   MYCN

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • BIRABRESIB   MYCN

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26631615


    Sources:
    CIViC

  • SONIDEGIB   MYCN

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24651015


    Sources:
    CIViC

  • PANOBINOSTAT   MYCN

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26733615


    Sources:
    CIViC

  • TRETINOIN   MYCN

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11107126


    Sources:
    NCI

  • ETOPOSIDE   MYCN

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12439032


    Sources:
    NCI

  • VINCRISTINE   MYCN

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12439032


    Sources:
    NCI

  • CYCLOPHOSPHAMIDE   MYCN

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12439032


    Sources:
    NCI

  • CISPLATIN   MYCN

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12439032


    Sources:
    NCI

  • Ensembl: ENSG00000134323

    • Version: 101_38

    Alternate Names:
    MYCN Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • CIViC: MYCN

    • Version: 14-September-2020

    Alternate Names:
    4613 Entrez Gene ID
    3741 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Carter et al., 2015, Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma., Sci Transl Med
    Kim et al., 2013, Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists., Cancer Cell
    Puissant A et al., 2013, Targeting MYCN in neuroblastoma by BET bromodomain inhibition., Cancer Discov

  • NCI: MYCN

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Reynolds et al., 2000, Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide., Med. Pediatr. Oncol.
    Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
    Anderson et al., 1999, Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis., Exp. Cell Res.

  • PharmGKB: MYCN

    • Version: 18-August-2020

    Alternate Names:
    PA31359 PharmGKB ID

    Gene Info:

    Publications:

  • Tempus: MYCN

    • Version: 11-November-2018

    Alternate Names:
    MYCN Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • MskImpact: MYCN

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: MYCN

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: MYCN

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: MYCN

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

  • Oncomine: MYCN

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21